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The BuFluTBI conditioning regimen was designed with the primary goal of reducing non-relapse mortality
(NRM)while maximizing primary disease control in patients ineligible formyeloablative conditioning. Patients
with hematologic malignancies for whom limited long-term survival was expected with standard therapy
were administered an outpatient conditioning regimen of busulfan 3.2 mg/kg IV on day5, ﬂudarabine 30mg/
m2 IV on days 4, 3, 2, and 200 cGy of total body irradiation (TBI) followed by stem cell infusion from
related or unrelated donors. GVHD prophylaxis included cyclosporine andmycophenolatemofetil. 147 patients
were enrolled from 2005-2011; 59%withmyeloid disease and 41% with lymphoid disease. The median agewas
64, and the median comorbidity index (HCT-CI) score was 3. Overall survival (OS), with 3.2 years median
follow-up, was 60% at 1 year and 48% at 2 years, with projected OS 37% at 5 years. Relapse rates were 29% at 1
year and 33% at 2 years, with relapsemortality of 13% at 1 year, and 20% at 2 years. Nonrelapsemortality (NRM)
at 1 year was 27% and 33% at 2 years. 54% of patients developed grade II-IV aGVHD and 67% of patients
developed cGVHD within 2 years. On multivariate analysis, HCT-CI score 4 or greater, pre-transplant KPS less
than 90, delayed platelet engraftment of more than 15 days, and grade II-IV aGVHD were found to be inde-
pendent predictors of poor survival. There was no difference in OS or PFS between lymphoid and myeloid
malignancies. BuFluTBI is an efﬁcacious NMA regimen, active in both myeloid and lymphoid disease, and is
ideally suited for use in patients age 65 and older or with an HCT-CI of 4 or greater.
 2015 American Society for Blood and Marrow Transplantation.INTRODUCTION
Allogeneic stem cell transplant remains the only curative
therapy for patients with high risk or relapsed hematologic
malignancies for whom limited long-term survival is ex-
pected with standard therapy. Over the past 2 decades, mul-
tiple nommyeloablative (NMA) and reduced-intensity
regimens have been developed for patients unable to toleratedgments on page 95.
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ty for Blood and Marrow Transplantation.conventional myeloablative conditioning regimens. Use of
these regimens has resulted in improved survival with
reduced nonrelapse mortality (NRM) [1-4]. The most com-
monof these regimens is the combination ofﬂudarabinewith
busulfan, melphalan, or low-dose total body irradiation (TBI)
[5-8]. The underlying principle of NMA conditioning relies
primarily on the immunosuppressive properties of the con-
ditioning regimen to allow engraftment and uses immuno-
competent donor cells to establish a graft-versus-tumor
effect to attain disease control [9]. However, any NMA
regimen must balance adequate immune suppression to
allow engraftment while also providing enough
Table 1
Baseline Transplant Characteristics at Time of Transplant
Characteristic Number of Cases
(%) (N ¼ 147)
KPS*
90 91 (66)
<90 48 (34)
HCT-CIy
0-3 60 (55)
>3 50 (45)
Age at transplant
65 yr 81 (55)
>65 yr 66 (45)
Pretransplant disease status
In CR 85 (58)
Not in CR 62 (42)
DRIz
Low or intermediate 93 (64)
High or very high 51 (36)
HLA match
8/8 135 (92)
7/8 12 (8)
Donor relation
Related sibling donor 39 (27)
Unrelated donor 108 (73)
CMV statusx
-/- recipient/donor 22 (16)
All other combinations 118 (84)
Donor/recipient gender
F/F, M/M, M/F 117 (80)
F/M 30 (20)
CMV indicates cytomegalovirus.
* Eight patients did not have KPS status available.
y Thirty-seven patients did not have HCT-CI score documented becasue
transplant evaluations were done before publication of the HCT-CI data.
z DRI was unclassiﬁable in 3 patients.
x
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prevent relapse.
The Seattle Consortium initially developed an NMA
regimen using 2 Gy TBI and ﬂudarabine, followed by cyclo-
sporine (CsA) and mycophenolate mofetil graft-versus-
host disease (GVHD) prophylaxis [10]. However, relapse
remained an issue, with 1-year progression-free survival
(PFS) of 38% observed in subsequent studies [11]. The addi-
tion of busulfan to ﬂudarabine is a leading NMA regimen
worldwide, with increased rates of disease control believed
to be related to the cytotoxic effects of busulfan. The Uni-
versity of Minnesota demonstrated efﬁcacy with a regimen
using 8 mg/kg busulfan with 2 Gy TBI and ﬂudarabine
200mg/m2, with excellent results [12]. At Oregon Health and
Science University (OHSU), the NMA regimen of 2 Gy TBI and
90 mg/m2 ﬂudarabine was used with high rates of donor
engraftment in the early 2000s as part of the Seattle Con-
sortium. However, relapses were seen in some cases,
particularly in patients with high-risk myelodysplastic syn-
drome (MDS) and transformed lymphoma [13,14]. Therefore,
in an effort to reduce relapse, a regimen using ﬂudarabine
90mg/m2 divided over 3 days, 2 Gy TBI, and busulfan 3.2 mg/
kg i.v. (BuFluTBI) was developed for the treatment of he-
matologic malignancies, with the goal of intensifying the
NMA ﬂudarabine/2 Gy TBI regimen.
The primary goal of the trial was to maintain low NRM
while maximizing disease control, thus improving overall
survival (OS) in patients unable to tolerate myeloablative
conditioning. Here we report transplant outcomes, regimen
safety data, and analysis of prognostic indicators with this
novel regimen.CMV status was unavailable in 7 patients.METHODS
Study Objectives
This trial was an institutional review boardeapproved, prospective,
phase II clinical trial initiated in July 2005, and the analysis herein repre-
sents follow-up as of January 1, 2012. The primary objective was to assess
NRM using the BuFluTBI regimen in patients with hematologic malignancies
at moderate to high risk for graft rejection and/or relapse of underlying
disease. Secondary objectives were OS, incidence of graft rejection, inci-
dence of grades II to IV acute GVHD (aGVHD), incidence of chronic extensive
GVHD, PFS, relapse-related mortality (RM), and nonhematologic grades III-
IV, and 5 organ-speciﬁc toxicity. Toxicities were graded according to the
National Institutes of Health Common Terminology Criteria for Adverse
Events, version 3 (Cancer Therapy Evaluation Program, Common Termi-
nology Criteria for Adverse Events, Version 3.0, DCTD, NCI, NIH, DHHSMarch
31, 2003 [http://ctep.cancer.gov]).Patient Selection
Inclusion criteria included patients aged 18 to 80 with hematologic
malignancies who were either not eligible or refused conventional mye-
loablative allogeneic stem cell transplant. Patients with hematologic ma-
lignancies treatable with an allogeneic stem cell transplant with limited
long-term survival expected with standard therapy were eligible. Eligible
patients had a fully HLA-matched related donor, HLA-matched unrelated
donor, or a 7/8 antigen or allele mismatched related donor or unrelated
donor.
Recipient exclusion criteria included rapidly progressive non-Hodgkin
lymphoma without partial remission status, limited life expectancy from
diseases other than malignancy, uncontrolled central nervous system (CNS)
involvement, positive HIV status, active nonhematologic malignancy other
than localized nonmelanoma skin cancers, fungal pneumonia with radio-
logic progression after 1 month of treatment, Karnofsky performance score
(KPS) less than 50, symptomatic coronary artery disease, ejection fraction
less than 35%, diffusing capacity of lung for carbon monoxide (DLCO) less
than 30%, forced expiratory volume in 1 second (FEV1) less than 30% or
receiving continuous oxygen, and severe liver disease. Additionally, patients
who had potentially curable illnesses with autologous stem cell transplant
were excluded. Patients were not permitted to have planned tandem
autologous followed by allogeneic stem cell transplant. After the publication
of the hematopoietic cell transplantation comorbidity index (HCT-CI) in2005, the HCT-CI was used and recorded for all patients for further risk
stratiﬁcation, selection, and analysis [15].Donor Selection
Donors were required to be fully HLA-matched (8/8) or single allelee or
antigen- (7/8) mismatched donors if no other donor was available. Donors
were required to be 18 to 69 years old for related donors or 18 to 60 years old
for unrelated donors and able to give consent for peripheral blood stem cell
mobilization with granulocyte colony-stimulating factor (G-CSF) and
apheresis collection. Exclusion criteria for donors included identical twin of
the recipient, contraindication to the administration of G-CSF, serious
medical or psychological illness, prior malignancy within the preceding
5 years (except for nonmelanoma skin cancers), HIV positivity, and preg-
nancy or lactating.Study Protocol
A protocol schematic can be seen in Supplemental Figure 1. Stem cell
source was ﬁlgrastim-mobilized peripheral blood from all related or unre-
lated adult donors. Patients received 4 days total of outpatient conditioning
chemotherapy and 1 day of TBI. Busulfan 3.2 mg/kg i.v. was administered on
day5, followed by ﬂudarabine 30 mg/m2/day on days 4, 3, and 2, and
2 Gy TBI at a rate of 15 to 19 cGy/min on day 0, followed by infusion of
peripheral blood stem cells. Initially, G-CSF was not part of the clinical
protocol, but a subsequent amendment allowed for G-CSF to be given at
5 mg/kg/day between days 10 and 15.
GVHD prophylaxis included mycophenolate mofetil 15 mg/kg twice
daily through day þ28 for related donors or 15 mg/kg three times daily
through day þ28 and then twice daily through day þ56 for unrelated do-
nors. CsA was administered with a starting dose of 4 mg/kg orally twice
daily from days 3 to þ56. Initially, because of concerns for graft rejection,
the target CsA level was 400 to 500 ng/mL through day þ28; however, this
goal was reduced when stable engraftment was demonstrated to a goal
level of 300 to 400 ng/mL. After day þ28, goal CsA levels, throughout the
study period, were 250 to 350 ng/mL. After day þ56, in the absence of
GVHD, CsA was tapered off by 6% every 7 days until day þ180. aGVHD was
graded on a scale of 0 to IV, using the Glucksberg organ-speciﬁc scale, with
GVHD occurring before 100 days [16]. Chronic GVHD (cGVHD) was deﬁned
Table 2
Transplant Characteristics by Disease Type
Descriptors No. Patients
(N ¼ 147)
Entire cohort
Median age, yr 64
Male, n (%) 98 (67)
Female, n (%) 49 (33)
AML (n) 62
Median age, yr (range) 66 (24-77)
AML type, n (%)
De novo 46 (74)
Therapy related 5 (8)
Secondary 11 (18)
Cytogenetics, n (%)
Good risk 2 (3)
Intermediate risk 41 (66)
High risk 19 (31)
Status at transplantation, n (%)
CR1 44 (71)
CR2 or beyond 11 (18)
Not in CR 7 (11)
Blast status at transplant
1% 25 (40)
1 < n<5% 34 (55)
5% 1 (2)
Unknown 2 (3)
MDS 19
Median age, yr (range) 66 (35-73)
MDS type, n (%)
De novo 13 (68)
Therapy related 6 (32)
Cytogenetics, n (%)
Good risk 8 (42)
Intermediate risk 3 (16)
High risk 8 (42)
Status at transplantation, n (%)
In CR 1 (5)
Not in CR 18 (95)
Blast status at transplant
1% 6 (32)
1 < n<5% 10 (53)
5% 1 (5)
Unknown 2 (10)
ALL 10
Median age, yr (range) 65 (52-72)
Status at transplantation, n (%)
CR1 8 (80)
CR2 2 (20)
CLL and PLL 17
Median age, yr (range) 59.5 (24-71)
In CR 3 (18)
Not in CR 14 (82)
CLL 14 (82)
PLL 3 (18)
Lymphoma 27
Median age, yr (range) 60 (18-71)
Lymphoma subtype
Hodgkin, n (%) 6 (22%)
Non-Hodgkin, n (%) 21 (78%)
B cell non-Hodgkin lymphoma
DLBC 4 (19%)
Mantle cell 7 (33%)
Nodal marginal zone B cell 1 (5%)
Follicular 4 (19%)
T cell non-Hodgkin lymphoma
Peripheral T cell 2 (10%)
Mycosis fungoides 1 (5%)
Angioimmunoblastic T cell 1 (5%)
Anaplastic, large T cell 1 (5%)
Plasma cell disorders 6
Median age, yr (range) 54.7 (39-64)
Plasma cell disorder subtype
Multiple myeloma 5 (83%)
Waldenström’s macroglobulinemia 1 (17%)
Other diseases 6
(Continued)
Table 2
(continued)
Descriptors No. Patients
(N ¼ 147)
Median age, yr (range) 63.5 (58-70)
Disease subtypes
CML 4 (66.6)
MPS 1 (1.7)
Blastic plasmacytoid dendritic cell leukemia 1 (1.7)
CLL indicates chronic lymphocytic leukemia; PLL, prolymphocytic leukemia;
DLBC, diffuse large B-cell lymphoma; CML, chronic myelogenous leukemia;
MPS, myeloproliferative syndrome.
Fifty-nine percent of patients hadmyeloid disease, with AML being themost
common disease type, representing 42% of all patients.
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transplant [17].
Chimerism either on peripheral blood or bone marrow were performed
on daysþ28,þ56,þ84,þ180, 1 year, and then annually for 5 years. Stem cell
infusion, infectious prophylaxis and monitoring, blood product adminis-
tration protocol, and disease assessments were performed according to
standard good clinical practice guidelines within the transplant department
at OHSU.
Statistical Analysis
Univariate probabilities of OS and PFS were estimated using the
Kaplan-Meier method [18]. Probabilities of relapse, RM, NRM, aGVHD, and
cGVHD were calculated using the cumulative incidence procedure to
accommodate for competing risks. A retrospective analysis of predictors of
OS, NRM, PFS, and RM was conducted. All patients were stratiﬁed retro-
spectively using the Armand disease risk index (DRI) [19]. The following
variables were analyzed in univariate and multivariate regression analyses
to identify factors that impacted clinical outcomes: KPS (90 or greater
versus 80 or less), age (65 or less versus over 65), comorbidity index (HCT-
CI of 3 or less versus 4 or greater), presence of complete remission (CR) at
transplant, DRI (low/intermediate versus high/very high), delayed absolute
neutrophil count (ANC) engraftment, delayed platelet engraftment, and
occurrence of any aGVHD or cGVHD. Cox proportional hazards regression
models were used for OS, PFS, NRM, RM, and relapse. Fine-Gray propor-
tional subdistribution hazards regression was performed for outcomes with
competing risks. Stata version 13.0 (Stata Corp., College Station, TX) was
used for all statistical analyses.
RESULTS
Baseline Transplant Characteristics
One hundred forty-seven patients with hematologic ma-
lignancies underwent allogeneic HCT at OHSU on this study
between July 2005 and December 2011: 86 (59%) patients
had myeloid disease and 61 (41%) had lymphoid disease.
Table 1 depicts disease and patient characteristics at the time
of transplant, and Table 2 depicts a breakdown of trans-
planted patients by disease type and status at transplant. The
median agewas 64 (range, 24 to 77), with amedian HCT-CI of
3. Fifty patients (45%) had an HCT-CI greater than 3. Ninety-
one patients (66%) had a KPS greater than or equal to 90,
whereas 48 patients (34%) had a KPS less than 90. The ma-
jority of patients (78%) had KPS between 80 to 90, and 4% had
KPS less than or equal to 70. At the time of transplant, 85
patients (58%) were in CR and 62 (42%) were not. One hun-
dred thirty-ﬁve patients (92%) were an 8/8 HLA match,
whereas 12 patients (8.2%) had a single mismatch (7/8). One
hundred eight patients (73%) received cells from unrelated
donors, whereas 39 patients (27%) received cells from
matched related donors. Thirty patients (20%) had female
donor allografts transplanted into a male recipient.
When stratiﬁed based on the DRI, 45 patients (31%) had
low risk, 48 patients (33%) had intermediate risk, 37 patients
(26%) had high risk, and 14 patients (10%) had very high risk
disease, with 3 unclassiﬁable. Because of the overall low
numbers in each group, the disease risk was condensed into
2 groups, low/intermediate and high/very high, for the
Table 3
Univariate Analysis of Prognostic Factors by Endpoint (N ¼ 147)
Category Comparison OS PFS NRM RM
HR CI P HR CI P HR CI P HR CI P
Disease status CR vs. no CR 1.66 1.10-2.51 .015* 1.80 1.20-2.69 .004* 1.41 .83-2.39 .206 2.17 1.12-4.19 .022*
HCT-CI score 0-3 vs. 4þ 1.82 1.18-2.81 .007* 1.85 1.14-3 .013* 2.33 1.24-4.38 .009* 1.83 .77-4.34 .169
Age at transplant, yr </65 vs. >65 1.94 1.05-3.57 .033* 1.67 0.91-3.05 .099 1.50 .64-3.50 .351 2.74 1.14-6.63 .025*
Pretransplant KPS <90 vs. >90 1.82 1.18-2.81 .007* 1.45 0.95-2.21 .087 1.71 1-2.94 .051 2.03 .98-4.22 .057
DRI score Low/intermediate
vs. high/very high
1.17 .77-1.78 .457 1.12 .75-1.69 .582 1.07 .62-1.82 .816 1.36 .70-2.64 .365
ANC engraftment </14 vs. >14 d 1.61 1.06-2.43 .025* 1.60 1.07-2.39 .021* 1.27 .75-2.15 .376 2.34 1.18-4.63 .015*
Platelet engraftment </15 vs. >15 d 1.73 1.10-2.71 .017* 1.67 1.08-2.58 .020* 2.18 1.25-3.8 .006* 1.14 .52-2.52 .740
aGVHD Grade 0-I vs. II-IV 1.45 .95-2.21 .081 1.35 .89-2.04 .158 1.70 .98-2.95 .057 1.15 .59-2.22 .679
cGVHD None vs. any .96 .53-1.75 .89 1.02 .53-1.98 .950 1.11 .49-2.48 .805 .80 .33-1.94 .619
* Denotes a statistically signiﬁcant P value.
J.E. Brammer et al. / Biol Blood Marrow Transplant 21 (2015) 89e9692purpose of analysis. Ninety-three patients (64%) had low/
intermediate risk disease, whereas 51 patients (36%) had
high/very high risk disease.
For the purpose of determining prognostic factors for
improved outcomes, univariate analysis was conducted in a
retrospective fashion on all patients with adequate data us-
ing 9 common variables associated with worse outcomes. On
univariate analysis for OS, pretransplant KPS, HCT-CI greater
than 3, absence of CR at transplant, age greater than 65, ANC
engraftment after day 14, and platelet engraftment after day
15 were associated with worse OS. HCT-CI greater than 3,
absence of CR at transplant, delayed ANC, and delayed
platelet engraftment were associated with worse PFS. HCT-CI
score greater than 3 and delayed platelet engraftment were
associated with worse NRM. The absence of CR, age at
transplant, and delayed ANC engraftment were associated
with worse RM. Univariate analysis results can be found in
Table 3.
For multivariate analysis, 110 patients were evaluated to
determine prognostic factors for OS, PFS, NRM, and RM. The
other 37 patients were excluded, because data were insufﬁ-
cient to include them within the multivariate analysis. OS,
PFS, NRM, and RMwere calculated on the 147-patient cohort,
but only 110 patients were included in the analysis for pre-
dictors of OS, PFS, NRM, and RM. The results of the multi-
variate analysis can be seen in Table 4 and are summarized
below.
OS Analysis
With a median follow-up of 3.2 years in living patients,
the 1-year OS was 60% and 2-year OS 48% (Figure 1). TheTable 4
Multivariate Analysis of Prognostic Factors by Endpoint (n ¼ 110)
Category Comparison OS PFS
HR CI P HR
Disease status CR vs. no CR 1.46 .81-2.64 .205 1.84
HCT-CI score 0-3 vs. 4þ 2.54 1.49-4.35 .001* 2.31
Age at transplant, yr </65 vs. >65 1.59 .94-2.69 .087 1.51
Pretransplant KPS <90 vs. >90 1.86 1.07-3.23 .028* 1.30
DRI score Low/intermediate
vs. high/very high
1.42 .79-2.57 .243 1.16
ANC engraftment </14 vs. >14 d 1.57 .88-2.80 .126 1.60
Platelet engraftment </15 vs. >15 d 1.79 1.02-3.15 .044* 1.69
aGVHD Grade 0-I vs. II-IV 1.84 1.06-3.20 .030* 1.31
cGVHD None vs. any 1.13 .54-2.36 .739 1.25
Multivariate analysis of 9 prognostic factors known to be associated with impaire
Thirty-seven patients were excluded from the analysis because of insufﬁcient data i
sufﬁcient information to be included. Separate analysis of the risk of relapse was d
* Denotes a statistically signiﬁcant P value.estimated 3-year and 5-year OS were 42% and 29%, respec-
tively. Of the 110 assessable patients for the purpose of
multivariate analysis, survival was inﬂuenced by an HCT-CI
score of 4 or greater (hazard ratio [HR], 2.54; 95% conﬁ-
dence interval [CI], 1.49 to 4.35; P ¼ .001), pretransplant KPS
less than 90 (HR 1.86; 95% CI, 1.07 to 3.23; P ¼ .028), delayed
platelet engraftment (HR 1.79; 95% CI, 1.02 to 3.15; P ¼ .044),
and the presence of grades II to IV aGVHD (HR 1.84; 95% CI,
1.06 to 3.20; P ¼ .030). DRI, presence of CR at transplant, age,
ANC engraftment, and cGVHD did not inﬂuence OS in the
multivariate analysis.
PFS Analysis
With a median follow-up of 3.2 years in living patients,
the 1-year PFS was 48% and 2-year PFS was 39% (Figure 1).
Estimated 3- and 5-year PFS based on Kaplan-Meier analysis
were estimated at 35% and 29%, respectively. In the 110
assessable patients for the purpose of multivariate analysis,
PFS was inﬂuenced by presence of CR at transplant (HR 1.84;
95% CI, 1.03 to 3.30; P ¼ .041) and an HCT-CI score of 4 or
greater (HR 2.31; 95% CI, 1.38 to 3.88; P ¼ .001). DRI, KPS at
transplant, presence of CR, age, ANC engraftment, platelet
engraftment, and presence of aGVHD or cGVHD did not in-
ﬂuence PFS in the multivariate analysis.
NRM Analysis
With a median follow-up of 3.2 years in living patients,
the 1-year NRM was 27% and 2-year NRM 33%. Cumulative
incidence of NRM at 3 and 5 years is estimated at 26% and
34%, respectively (Figure 2A). In multivariate analysis, an
HCT-CI score of 4 or greater (HR 2.15; 95% CI, 1.12 to 4.10;NRM RM
CI P HR CI P HR CI P
1.03-3.30 .041* 1.27 .58-2.75 .552 1.38 .49-3.87 .545
1.38-3.88 .001* 2.15 1.12-4.10 .021* 1.39 .56-3.46 .481
.91-2.48 .108 1.72 .90-3.29 .100 1.01 .37-2.75 .988
.77-2.17 .325 1.44 .76-2.76 .265 1.62 .59-4.43 .348
.66-2.04 .598 1.11 .50-2.46 .798 1.60 .64-4.01 .312
.93-2.76 .090 1.35 .68-2.71 .393 2.01 .81-4.96 .130
.99-2.88 .052 1.57 .77-3.19 .211 1.00 .35-2.88 .995
.78-2.23 .310 2.17 1.17-4.04 .015* .90 .32-2.54 .840
.59-2.66 .561 2.05 .98-4.29 .058 1.78 .62-5.12 .288
d stem cell transplant outcomes were analyzed for OS, PFS, NRM, and RM.
n all 9 prognostic factors to include in the analysis. A total of 110 patients had
one, and no statistically signiﬁcant prognostic factors were identiﬁed.
Figure 1. Kaplan-Meier estimates of OS and PFS. With a median follow-up of
3.2 years in living patients, the 1-year OS was 60% and 2-year OS 48%. The
estimated 3-year and 5-year OS were 42% and 29%, respectively. With a me-
dian follow-up of 3.2 years in living patients, the 1-year PFS was 48% and 2-
year PFS 39%. Estimated 3- and 5-year PFS based on Kaplan-Meier analysis
were estimated at 35% and 29%, respectively.
Figure 2. (A) Cumulative incidence of NRM. With a median follow-up of
3.2 years in living patients, the 1-year NRM was 27% and 2-year NRM 33%.
Cumulative incidence of NRM at 3 and 5 years is estimated at 26% and 34%,
respectively. (B) Cumulative incidence of relapse. The cumulative incidence of
relapse was 29% at 1 year and 33% at 2 years. With a median follow-up of
3.2 years in living patients, the 1-year RM was 13% and 2-year RM was 20%.
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were associated with increased risk of NRM. DRI, KPS, pres-
ence of CR, age, ANC engraftment, platelet engraftment, and
the presence of cGVHD did not inﬂuence NRM in the multi-
variate analysis.
Relapse Analysis
The cumulative incidence of relapsewas 29% at 1 year and
33% at 2 years (Figure 2B). With a median follow-up of
3.2 years in living patients, the 1-year RMwas 13% and 2-year
RM was 20%. Despite signiﬁcance for disease status, ANC
engraftment, and age on univariate analysis, in the multi-
variate analysis neither relapse mortality (Table 4) nor
relapse (data not shown) were associated with the presence
of CR, HCT-CI score, age, pretransplant KPS, DRI score, ANC
engraftment, platelet engraftment, and aGVHD or cGVHD.
Graft-Versus-Host Disease
Grades II to IV aGVHD occurred in 79 patients (67%). The
cumulative incidence of grades II to IV aGVHD was 55% at
100 days and 60% at 6 months. Because the initiation of the
study predated the 2005 National Institutes of Health
consensus criteria on cGVHD, cGVHD was graded based on
the limited/extensive classiﬁcation system. Ninety-nine pa-
tients (67%) developed cGVHD, 86 patients (87%) with
extensive stage cGVHD and 13 patients (13%) with limited
stage cGVHD. The cumulative incidence of cGVHD was 64.6%
at 1 year, 66% at 2 years, and 67.3% at 3 years.
Outcomes among Patients with Myeloid and Lymphoid
Malignancies
OS in patients with myeloid disease was 61% at 1 year and
43% at 3 years, whereas OS for lymphoid diseasewas 55% and
33% at 1 and 3 years, respectively. However, there was no
statistically signiﬁcant difference in OS between the
lymphoid and myeloid groups (P ¼ .71). There was a trend
toward improved PFS in the myeloid versus lymphoid group
(P ¼ .08).
Sixty-two patients were treated for acute myeloid leu-
kemia (AML) using the BuFluTBI conditioning regimen, rep-
resenting the largest disease cohort. Forty-four of thesepatients (71%) were in ﬁrst complete remission (CR1) at
transplant, whereas 18 (29%) were not. In patients in CR1 at
transplant at 3 years, OS and PFS were 47%, cumulative
incidence of NRM was 38%, and rate of relapse was 25%. In
patients not in CR1 at transplant, OS was 23.1%, PFS was
25.9%, and cumulative incidence of NRMwas 43.7%, with rate
of relapse of 50%.
There was no statistically signiﬁcant difference in OS in
patients with AML versus the entire cohort (P ¼ .42). How-
ever, PFS for AML trended toward signiﬁcance versus all
other disease (P ¼ .06). The OS in patients with AML at 1 year
and 2 years was 68% and 49%, respectively, compared with
the OS of patients with MDS of 47% at 1 year and 41% at
2 years. This was approaching statistical signiﬁcance at 1 year
(P ¼ .07) and 2 years (P ¼ .11), but beyond 2 years, the curves
intersected and there was no statistically signiﬁcant differ-
ence (P ¼ .22). Patients with MDS were noted to have
increased NRM within the ﬁrst year after transplant. Of the
10 patients who died by the 1-year mark, 8 died of NRM and
2 from relapse.
Transplant-Related Toxicities
There were 124 events of grade III/IV toxicity within the
ﬁrst 100 days as noted in Table 5. Most events were hepatic
toxicity with 38 incidences of hyperbilirubinemia or trans-
aminitis. There was 1 episode of grade III veno-occlusive
disease at day þ37. There were 21 incidents of cardiac
Table 5
Regimen Related Grade III/IV Toxicities within the First 100 Days
Grade Cardiac Renal Pulmonary Hepatic CNS Other Total
Events 21 10 8 39 16 30 124
III 15 6 6 35 12 25 96
IV 6 4 2 4 4 5 25
Grade III or IV toxicities are reported by organ system. There were a total of
124 grade III/IV events within the ﬁrst 100 days. Most events were hepatic
toxicity, with 38 incidences of hyperbilirubinemia or transaminitis.
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systolic dysfunction, 1 had a pericardial effusion, and 3 had
atrial ﬁbrillation/ﬂutter. Of grade IV cardiac events, 1 patient
had left ventricular dysfunction, 1 patient had pericardial
effusion, and 1 had respiratory pulseless electrical activity
(PEA) arrest. There were 10 renal events with 1 grade III
event associated with CsA. There were 8 pulmonary events,
of which there was 1 episode of cryptogenic organizing
pneumonia and 1 episode of eosinophilic pneumonia. There
were a total of 16 CNS events, with 5 episodes associated
with CsA toxicity. Of these CNS events, there were 2 episodes
of posterior-reversible encephalopathy syndrome. One of
these events was associated with CsA toxicity. There were 30
other grade III/IV toxicities, including iron overload (n ¼ 1),
steroid myopathy (n ¼ 3), hemolysis (n ¼ 5), ABO incom-
patability associated hemolysis (n ¼ 1), bleeding (n ¼ 2),
thrombosis/deep vein thrombosis (n ¼ 5), thrombotic
thrombocytopenic purpura (TTP) (n ¼ 1), refractory ascites
(n ¼ 1), Ogilvie’s syndrome (n ¼ 1), and fractures/musculo-
skeletal (n ¼ 3).
Infectious Complications
There were 21 recorded infectious complications associ-
ated with the transplant. Most of these (n ¼ 14) were neu-
tropenic fever. Seventeen patients died of infectious causes
or sepsis. Of these, 7 were bacterial, 3 were fungal, 3 died of
sepsis/septic shock, and 4 were other infectious causes un-
speciﬁed (3 viral, 1 nonspeciﬁed pneumonia).
Causes of Death
With a median follow-up time of 3.2 years, 94 patients
had died. Two deaths occurred before day þ28: 1 patient
with renal failure and another with cirrhosis. There were no
other deaths before day þ28. There was 1 episode of graft
failure and death on dayþ85. Other causes of death included
aGVHD (n ¼ 8), cGVHD (n ¼ 10), new primary lung cancer
(n ¼ 1), cardiac failure (n ¼ 4), multisystem organ failure
(n ¼ 2), failure to thrive (n ¼ 6), massive stroke (n ¼ 1),
Parkinson disease (n ¼ 1), chronic obstructive pulmonary
disease (n ¼ 1), idiopathic interstitial pneumonia (n ¼ 1),
pneumonia not otherwise speciﬁed (n ¼ 1), pulmonary
failure not otherwise speciﬁed (n ¼ 1), thromboembolism
(n¼ 1), gastrointestinal organ failure not otherwise speciﬁed
(n ¼ 1), infection/sepsis (n ¼ 17), recurrent/persistent dis-
ease (n ¼ 35), and unknown (n ¼ 1).
Engraftment and Chimerism
One incident of graft failure occurred at day þ85. One
hundred seven patients (73%) achieved platelet engraftment
by day þ15 or less, and 39 patients (27%) achieved platelet
engraftment after 15 days. Median time to platelet engraft-
ment was 10 days and median time to ANC engraftment was
14 days.
By day þ84, 50% of assessable patients (65/129) had
achieved 100% CD3 and CD33 donor chimerism by blood orbone marrow. Of the remaining 64 patients, 61 (95%) had
greater than 50% donor chimerism, with a median CD3
chimerism of 92% and median CD33 chimerism of 100%.
Fifteen patients had died before day þ84 and 3 did not have
available chimerism data. At 1 year, 92% of assessable sur-
viving patients (101/110) had full donor chimerism by pe-
ripheral blood or bonemarrow, and all but 1 of the remaining
9 patients had more than 50% chimerism for both CD3 and
CD33.
Readmission Rates
Given that the BuFluTBI regimen was administered pri-
marily on an outpatient basis, the rate of readmission at
30 days and 100 days was evaluated. By dayþ30, 70 patients
(47.6%) were readmitted, often for their ﬁrst neutropenic
fever. By day 100, 104 (70.7%) patients experienced hospital
readmission, with later admits having more diverse pre-
sentations including relapse, infections, and emergence of
GVHD.
DISCUSSION
BuFluTBI is an efﬁcacious NMA regimen with acceptable
levels of NRM for the treatment of hematologic malignancies.
This single-institution study demonstrates that in an elderly
and inﬁrm cohort of patients, this outpatient-based regimen
was well tolerated and efﬁcacious. One-year OS was 60%,
with 2-year OS of 48%, and projected 3- and 5-year OS of 42%
and 29%, respectively. These outcomes are coupled with
acceptable rates of NRM at 27% at 1 year, and 33% at 2 years,
with low rates of relapse (29% at 1 year, 33% at 2 years). All
are comparable with other known NMA regimens. Addi-
tionally, in this study we present the results of a large cohort
of patients (n ¼ 147) with a median long-term follow-up of
3.2 years.
Of particular interest in this cohort of patients was the
high comorbidity index (HCT-CI) and advanced age of pa-
tients. The average age of patients was 64 years, with a
median HCT-CI of 3: 45% of patients had an HCT-CI of 4 or
more, and 34% had KPS scores less than 90%. A median age of
64 is signiﬁcantly higher than the aforementioned landmark
NMA protocols, with median ages ranging from 52 to
60 years [5-8]. On multivariate analysis, age was not an in-
dependent predictor of OS (P ¼ .087) or NRM (P ¼ .1). How-
ever, OS was effected by pretransplant KPS (HR, 1.86;
P ¼ .028) and HCT-CI scores of 4 or more (HR, 2.54; P ¼ .001).
Additionally, NRM was signiﬁcantly affected by the HCT-CI
score of 4 or greater as well (HR, 2.15; P ¼ .021). As ex-
pected, aGVHD affected OS and NRM, and cGVHD
approached signiﬁcance (P ¼ .058) for NRM.
These data further demonstrate that age alone is not a
contraindication to a potentially curative allogeneic trans-
plant but rather HCT-CI and performance status adversely
affect OS and NRM. The BuFluTBI regimen provides low NRM
while providing adequate disease control in patients with a
high HCT-CI and low KPS. These ﬁndings are in keeping with
an analysis of treatment-related mortality and OS in elderly
patients undergoing induction for AML [20]. In that study,
age was a surrogate marker for impaired survival. Patients
were stratiﬁed by age, thrombocytopenia, and impaired
performance status and assigned risk groups based on these
covariates. Although age did predict for worse OS in that
study, it was suggested by the authors that agewas primarily
a surrogate for other risk factors, of which platelet count and
performance status were the most signiﬁcant. Our data
support these observations in the transplant setting, where
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age did not. To best select patients who will most beneﬁt
from allogeneic transplant, a rigorous stratiﬁcation system
was recently reported by Mufﬂy et al. [21] using a geriatric
assessment tool as screening for elderly patients referred for
consideration of allogeneic transplant. In considering elderly
patients for allogeneic stem cell transplant, tools such as
these may help to identify patients with advanced age who
will most beneﬁt from transplant beyond the HCT-CI.
In an attempt to classify the risk of disease in this study,
patients were stratiﬁed based on the Armand DRI and 69%
were found to have intermediate, high, or very high risk
disease. Although there was no statistically signiﬁcant effect
on OS or NRM based on these groups on multivariate anal-
ysis, this cohort represents a representative sample of pa-
tients with both aggressive and indolent histologies for
which the BuFluTBI regimen is effective. The lack of impact of
DRI on OS and NRM likely was related to the relatively small
population of patients compared with the initial data from
Armand et al. [19].
In this study, all patients with hematologic malignancies
were included, with 59% of patientswithmyeloid disease and
41% with lymphoid disease. There was no statistically signif-
icant difference in OS between the myeloid and lymphoid
groups (P¼ .42), suggesting the BuFluTBI regimen is effective
in both lymphoid and myeloid disease. Interestingly, among
AML and MDS, when separated from the entire cohort, pa-
tients with AML tended to have superior outcomes when
compared toMDS,with a trend toward improved survival at 1
(P¼ .07) and 2 years (P¼ .11). The reasons for this are unclear,
but there was increased NRM observed in the ﬁrst year in
MDS patients. Before the approval of the Coverage with Evi-
dence Development program for MDS by the Centers for
Medicare & Medicaid Services in 2010, elderly patients with
MDS, of whommostwere of advanced age onMedicare, were
infrequently offered or referred for allogeneic transplant.
Once the Coverage with Evidence Development was
approved, patients referredmay have been higher risk due to
prolonged cytopenias, multiple courses of therapy, and
increased infectious risk and complications. It is conceivable
that the increase in NRMmay be due to this trend of patients
being referred later for transplant based on coverage eligi-
bility or physician referral patterns. Understanding the nat-
ural history of MDS and determining the role of transplant in
this population is the focus of the current CTN 1102 trial.
BuFluTBIwas safe in a higher risk population. Therewere8
incidents of grade III/IV pulmonary toxicity, with 2 incidents
of pulmonary-associated death: 1 patient with pneumonia
and another with idiopathic interstitial pneumonia. It did not
appear that the addition of busulfan to the FluTBI regimen
signiﬁcantly increasedpulmonary toxicity comparedwith the
2 Gy TBI/Flu regimen inwhich there were 7 cases of grade III/
IV toxicity [10]. There was 1 incident of veno-occlusive dis-
ease, but overall there didnot appear to be an increased risk of
veno-occlusive disease with the addition of i.v. busulfan.
Additionally, there was only 1 graft rejection event out of
147 patients. Adequate immune suppression to promote
engraftment was demonstrated with median CD3 chimerism
of 92% and median CD33 chimerism of 100% at day þ84 and
92% of patients achieving 100% CD3 and CD33 chimerism by
1 year. Of note, most neurologic toxicities were associated
with cyclosporine, andmost hepatic toxicities were transient
rises in liver function tests (LFTs) or bilirubin. Furthermore, by
dayþ30, 47.6% of patients were readmitted, and by dayþ100,
70.7% of patients were readmitted. Given the high HCT-CI andadvanced age of this cohort, these readmission rates and
toxicities are reasonable and demonstrate the tolerability of
this regimen in the outpatient setting.
Although this conditioning regimen proved effective in an
elderly and inﬁrm population, mortality still remained high in
patients with HCT-CI of 4 or more (OS HR 2.54) and KPS less
than 90 (OS HR 1.86). Despite the impaired survival in this
particularly high-risk group of patients, these patients likely
would have higher NRM with a more intense conditioning
regimen or may have been unable to proceed with potentially
curative transplant without the availability of the BuFluTBI
regimen at our institution. Further subgroup analysis of these
high-risk patients, with stratiﬁcation based on HCT-CI, may
identify the subgroups of patients with high HCT-CI or low
KPS who would beneﬁt most from a stem cell transplantation
or not at all. By selecting out these patients, it may be possible
to best identify the subgroup of patients with high HCT-CI and
low KPS who most beneﬁt from this regimen. Additionally,
relapse remained the second most common cause of treat-
ment failure, with 2-year RM of 20%. Relapse remains a major
cause of treatment failure within the ﬁeld of stem cell trans-
plantation, and a National Cancer Institute committee focused
on the prevention and treatment of relapse was formed in
2011 [22]. Particularly in patients undergoing NMA or
reduced-intensity transplants, a maintenance strategy post-
transplant may help to decrease relapse. This approach has
been successful after autologous transplantwith lenalidomide
and is currently being explored with the use of maintenance
azacitidine with promising preliminary results [23,24].
A similar approach, coupled with effective salvage therapies
and novel agents, may help to improve the incidence of
relapse and RM in patients receiving the BuFluTBI regimen.
In summary, BuFluTBI is an efﬁcacious NMA conditioning
regimen for both lymphoid and myeloid disease, with
acceptable rates of NRM. The outcomes of this regimen are
comparable with other NMA conditioning regimens in 1 of
the highest risk and elderly populations evaluated to date,
with a median age of 64 and median HCT-CI of 3. Given the
availability of multiple NMA conditioning regimens,
BuFluTBI is ideally suited for use in patients over age 65 or
with an HCT-CI of 4 or greater to attain disease control and
improve survival.
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